Skip to main content
. 2015 Jun 5;5:11030. doi: 10.1038/srep11030

Figure 2. Adjuvant VT improves survival even if delayed.

Figure 2

(a) C57BL/6J mice were infected with mouse-adapted influenza, strain X31 and received daily amantadine (Amant) starting at the time of infection; placebo or daily 500 ng VT was given starting 72 hours later, **p < 0.01, ***p < 0.001 vs. flu-alone mice. Numbers in parentheses indicate the number of mice per group. (b) Arterial oxygen saturation was measured 6 days after viral infection, **p < 0.01, ***p < 0.001 versus Flu/Amant/VT72. (c) Body temperature measured 5 days after infection, *p < 0.05 , **p < 0.01 vs. Flu/Amant/VT72 (d) Fraction of initial body weight measured 5 days after infection, *p < 0.05, **p < 0.01 vs. Flu/Amant/VT72.